EHR-based NYC Macroscope collects population data with chronic disease surveillance

Rates of chronic conditions across populations are key data points in improving people health. While electronic health records (EHRs) are able to offer real-time standardization of health information, chronic disease surveillance is low. A study, published by eGEMs, reports how the New York City (NYC) Macroscope could improve the status quo.

The NYC Macroscope, an EHR-based chronic disease surveillance system, was designed to be comparable to the 2013-14 NYC Health and Nutrition Examination Survey and the telephonic 2013 Community Health Survey. Macroscope is able to examine prevalence of influenza, obesity, depression, smoking rates, vaccinations, treatments, diabetes, hypertension and hyperlipidemia, sorting such data by age, sex and poverty within patient populations.

The report included 392 practices and 716,076 adult patients, covering 10 percent of primary care providers and 15 percent of all adult patients from 2013. Depending on a patient’s domain, data collection was completed from 98 percent for blood pressure in patients with hypertension to 33 percent for depression screening.

“Design and validation efforts undertaken by NYC are described here to provide one potential blueprint for leveraging EHRs for population health monitoring,” concluded Remle Newton-Dame, of the NYC Department of Health and Mental Hygiene, and colleagues. “To replicate a model like NYC Macroscope, jurisdictions should establish buy-in, build informatics capacity, use standard and simple case definitions, establish documentation quality thresholds, restrict to primary care providers and weight the sample to a target population.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.